The importance of histological assessment after neoadjuvant therapy and the need for standardisation
Neoadjuvant therapy is increasingly being recognised as a management option for patients with primary invasive breast carcinoma; this may take the form of primary endocrine treatment or primary chemotherapy. Surgical specimens from women treated with neoadjuvant treatments, particularly primary chemotherapy, may cause a challenge for the histopathologist in handling and interpretation and have, in the past, been sampled, evaluated, and reported in a non-standardised way. This limits comparison between clinical trials and potentially provides clinicians and patients with suboptimal prognostic information.
Source: Clinical Radiology - Category: Radiology Authors: K. Naidoo, S.E. Pinder Tags: Review Source Type: research
More News: Breast Carcinoma | Cancer & Oncology | Carcinoma | Chemotherapy | Clinical Trials | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Radiology | Women